ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, announces the commercial release of LENS API, hereafter referred to as the ‘software’,...
Significant throughput of LSA to advance IPA’s diversity- and data-driven drug development and to enrich LENSai™.
IPA, an artificial intelligence-driven biotherapeutic research and technology company,...
IPA, an artificial intelligence-driven biotherapeutic research and technology company, announced the development of a Foundation AI Model that represents a significant advancement in life...